Zacks Investment Research
11 Jun 2026, 22:51 UTC · 2h ago
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
11 Jun 2026, 22:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
CRISPR Therapeutics AG is projected to see quarterly revenue growth of 942.7% compared to the prior-year quarter. — Massive revenue growth indicates a significant commercial scale-up or new product launch, which is a primary driver for biotech valuations.
+0.60Zacks Consensus EPS estimates for CRISPR Therapeutics AG have increased by 3.99% over the past month. — Positive analyst revisions generally correlate with near-term upward price movement.
+0.30The Medical - Biomedical and Genetics industry is ranked in the bottom 38% of all industries according to Zacks. — Poor industry-wide ranking suggests systemic headwinds for companies within this specific biotech niche.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
CRISPR Therapeutics AG currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating suggests a neutral outlook, indicating a lack of strong conviction for immediate buying or selling.
Which stocks this story touches
Positive revenue and earnings growth forecasts, along with a 3.99% upward revision in consensus EPS estimates, despite a recent stock price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
